TMED3 and glioblastoma: In addition, Liao et al. found that TMED3 was substantially expressed in gliomas, to be connected to tumor stage, and to have an impact on patient prognosis, according to Liao et al. TMED3 could therefore be a viable immunotherapeutic target and prognostic marker for glioblastoma.